Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's Disease (NCT04664634)

Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's Disease (NCT04664634)

Trial Overview

| Field | Value |
|-------|-------|
| NCT ID | NCT04664634 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Northwestern University |
| Enrollment | 60 participants |
| Start Date | September 2023 |
| Completion Date | December 2025 |

Study Design

Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's Disease (NCT04664634)

Trial Overview

| Field | Value |
|-------|-------|
| NCT ID | NCT04664634 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Northwestern University |
| Enrollment | 60 participants |
| Start Date | September 2023 |
| Completion Date | December 2025 |

Study Design

This randomized, controlled Phase 3 trial evaluates a novel digital therapeutic platform designed to treat dysphagia (swallowing difficulties) and sialorrhea (excessive drooling) in Parkinson's Disease patients. The platform combines sensor-based monitoring with targeted exercises.

Mechanism

The digital therapeutic platform utilizes:

Inclusion Criteria

• Age 50-85 years
• Diagnosed with Parkinson's Disease
• Clinically significant dysphagia or sialorrhea
• Stable PD medication regimen
• Access to smartphone/tablet

Exclusion Criteria

• Severe cognitive impairment (MMSE < 20)
• Recent stroke or neurological event
• Structural esophageal disease
• Active dental issues affecting drooling

Outcome Measures

Primary Outcomes

• Change in Swallowing Quality of Life (Swal-QoL) score
• Change in Drooling Severity and Frequency Scale (DSFS)

Secondary Outcomes

• Timed swallowing tests
• Patient satisfaction ratings
• Caregiver burden assessments

Clinical Significance

Dysphagia and sialorrhea are debilitating non-motor symptoms affecting up to 50% of PD patients. This digital therapeutic approach offers a non-pharmacological, accessible treatment option that can be used at home.

Dysphagia in Parkinson's Disease

Prevalence and Impact

Dysphagia (swallowing difficulties) affects 30-50% of Parkinson's disease patients[@dysphagia2023]:

• Progressive nature: Often worsens with disease duration
• Quality of life: Significant impact on nutrition, social eating
• Mortality risk: Aspiration pneumonia is a leading cause of death in PD

Pathophysiology

Multiple factors contribute to dysphagia in PD:

• Oral phase dysfunction: Delayed swallow initiation, residue
• Pharyngeal phase impairment: Reduced pharyngeal clearance
• Esophageal dysmotility: Reduced peristalsis
• Postural instability: Trunk flexion affects swallowing mechanics

Current Management Options

| Approach | Efficacy | Limitations |
|----------|----------|--------------|
| Swallowing exercises | Moderate | Requires therapist, compliance |
| Diet modification | Variable | Reduces quality of life |
| Botulinum toxin | Good for sialorrhea | Invasiveness |
| Surgical | Variable | Risks |

Sialorrhea in Parkinson's Disease

Pathophysiology

Sialorrhea (excessive drooling) in PD results from[@sialorrhea2024]:

• Reduced swallowing frequency: Automatic swallowing reduced in PD
• Impaired saliva clearance: Tongue and lip movements affected
• Postural factors: Forward head position increases drooling

Treatment Approaches

• Anticholinergic medications: Side effects limit use
• Botulinum toxin injections: Effective but invasive
• Speech therapy: Limited efficacy alone
• Behavioral interventions: Promising but understudied

Digital Therapeutic Platform

Technology Description

The digital therapeutic platform offers several innovative features[@digital2024]:

Clinical Benefits

• Accessibility: Home-based treatment reduces clinic visits
• Compliance tracking: Objective measurement of treatment adherence
• Personalization: Adaptive exercises based on performance
• Cost-effectiveness: Lower cost than traditional therapy

Study Protocol

Treatment Duration

• Intervention period: 8-12 weeks
• Daily session length: 15-30 minutes
• Follow-up: 3-month post-treatment assessment

Outcome Measures

Primary endpoints:

• Swallowing Quality of Life (Swal-QoL) score
• Drooling Severity and Frequency Scale (DSFS)

• Timed water swallow test
• Functional Oral Intake Scale (FOIS)
• Patient and caregiver satisfaction

Regulatory Status

Digital therapeutics for neurological conditions are an emerging field:

• FDA cleared: Several digital therapeutics for movement disorders
• Reimbursement: Increasingly covered by insurance
• Clinical validation: Growing evidence base supports efficacy

Comparison with Traditional Approaches

| Feature | Traditional Therapy | Digital Therapeutic |
|---------|---------------------|---------------------|
| Location | Clinic-based | Home-based |
| Frequency | 1-2x/week | Daily |
| Cost | Higher | Lower |
| Compliance tracking | Limited | Objective |
| Personalization | Therapist-dependent | Algorithm-based |

Related Pages

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Non-Motor Symptoms of PD](/mechanisms/non-motor-symptoms-parkinsons)
• [Digital Therapeutics for Neurodegeneration](/therapeutics/digital-therapeutics-neurodegeneration)
• [Dysphagia Management](/therapeutics/dysphagia-management)
• [Botulinum Toxin for PD](/clinical-trials/botulinum-toxin-cbs-dystonia-nct05678901)

References